Previous studies reported that activity of CDK9 was involved in maintaining a high expression level of MDM4 in human cells, and drugs targeting CDK9 might restore p53 tumor suppressor function in malignancies overexpressing MDM4 [34]. The gene discussed is TP53; the disease is neoplasm.